

Suven Life Sciences secures three product patents

14 July 2015 | News | By BioSpectrum Bureau

Suven Life Sciences secures three product patents



Suven Life Sciences (Suven) has announced that they have secured patents in China (CN103443093) and South Africa (2013/01143, 2013/06328) to their New Chemical Entities (NCE's) for CNS therapy through mechanism of action - H3 Inverse agonist and these patents are valid until 2031, 2030 and 2031 respectively.

The granted claims of the patent include the class of selective H3 ligands discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders.

Suven also secured a patent for their NCE in Mexico (326651) and the granted claims of this patent include the class of selective alpha-4-beta-2 compounds discovered by Suven and are being developed as therapeutic agents for major depressive disorder (MDD) and the patent is valid through 2030.

With these new patents, the company has a total of sixteen (16) granted patents from China, nineteen (19) granted patents from Mexico and twenty two (22) granted patents from South Africa.

"We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally," said Mr Venkat Jasti, CEO of Suven.